Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPLUS: IP Paclitaxel + mFOLFOX6 in Gastric Cancer
NCT03618758Phase 2Completed
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Dec 2018
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in gastric cancer (GC), sponsored by Seoul National University Bundang Hospital. Primary endpoints: Dose determination (Phase 1) at 1 year and Overall Survival at 1 year. Started Dec 2018; status: completed.
02
Drugs
paclitaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03618758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618758.